Insurtech Statistics (2026)

After a brutal three-year contraction, insurtech is stabilizing. Global funding rose 19.5% to $5.08 billion in 2025, the first annual increase since the 2021 mania, and exits finally reopened with 6 IPOs. But this is a leaner, more selective sector than the one that raised $15.8 billion in 2021.

Two forces define the moment: artificial intelligence, which absorbed about two-thirds of all 2025 funding, and traditional carriers and reinsurers, who wrote a record 162 direct checks. The froth is gone; capital now chases proven scale and real underwriting results, not growth-at-all-costs experiments.

Global insurtech investment reached $5.08 billion in 2025, up 19.5% from $4.25 billion in 2024, according to Gallagher Re (see the chart and table below). It was the first year-over-year increase since the sector peaked, a modest but meaningful inflection after a long slide.

The recovery was back-half loaded. Q4 2025 alone brought in $1.68 billion, a 66.8% jump over Q3 and the largest quarterly total since Q3 2022. The rebound was driven by returning mega-rounds and a wave of strategic capital from insurers themselves.

The funding-dollar picture masks a sharper drop in activity. CB Insights counted 362 insurtech deals in 2024, down 28% from 500 in 2023, even as total funding dipped only 4% (from $4.7 billion to $4.5 billion on their tally). Fewer deals, but bigger ones.

That divergence is the story of the whole cycle: median deal size rose from $4.1 million in 2023 to $5.2 million in 2024, and median early-stage rounds surged 52% to $3.8 million. Money concentrated into a smaller set of higher-conviction bets (CB Insights).

The 2025 quarterly path shows the recovery building through the year (see the chart and table below). After a soft Q2 ($1.09 billion) and Q3 ($1.01 billion across 49 deals), Q4 exploded to $1.68 billion across 102 deals, with average deal size up 20% to $18.84 million.

The Q4 surge was not broad-based froth. It was concentrated in large, late-stage and AI-focused rounds, with carriers and reinsurers unusually active. Q3 2025's deal count of 49 had marked one of the quietest quarters on record before the year-end snap-back.

Artificial intelligence has become the center of gravity. Two-thirds of all 2025 insurtech funding, $3.35 billion across 227 deals, went to companies Gallagher Re classifies as AI-focused. The concentration intensified as the year went on: AI captured 74.8% of Q3 funding and 77.9% of Q4.

Underwriting is the killer application. Startups like Sixfold (a $30M Series B backed by Guidewire) and Federato are building AI that reads submissions, assesses risk, and drafts quotes, the slow, human-heavy core of insurance. Investors are betting AI compresses the loss-and-expense ratios that decide whether an insurer makes money.

The clearest sign of thaw is the return of the $100M-plus round. The count nearly doubled from 6 in 2024 to 11 in 2025 (see the table below). The largest included Openly ($193 million for homeowners insurance), CyberCube ($180 million in cyber-risk analytics), and satellite-data firm ICEYE ($174.8 million Series E).

Every one of the 11 mega-round recipients had reached a scaling or later maturity stage, per CB Insights. Capital is flowing to companies with real revenue and distribution, not pre-product concepts, a complete reversal of the 2021 playbook where early-stage stories commanded premium valuations.

The investor base has thinned dramatically. Only 15 investors made 4 or more insurtech investments in 2025, the fewest since 2016, and the count of firms doing 5-plus equity deals fell from 57 in 2021 to just 7 in 2024. The generalist tourists have left.

In their place: the industry itself. Insurers and reinsurers made a record 162 direct technology investments into insurtechs in 2025 (Gallagher Re). Strategic capital now underwrites the sector, which favors startups with a clear path to partnering with, or being bought by, an incumbent.

For years the exit door was bolted shut. That changed in 2025: 6 insurtechs went public, up from 3 in 2024 and zero in 2023, and M&A exits hit a multi-year high. Combined IPO and M&A activity rose about 67% year over year, outpacing the broader venture market.

The reopening matters because it recycles capital and sets valuation benchmarks. CB Insights flagged companies like Alan and Coalition with roughly 58% modeled odds of an IPO within two years, suggesting the late-stage pipeline that built up during the drought is finally starting to clear.

Ask how large the insurtech market is and you will get answers spanning an order of magnitude (see the table below). Grand View Research pegs it near $152 billion by 2030 (52.7% CAGR from a $5.45 billion 2022 base), while SkyQuest projects $876 billion by 2033. These are secondary estimates and should be read with caution.

The gap comes from definitions. Narrow measures count only pure-play insurtech software and platforms; broad ones fold in all digitally distributed premium, which is measured in trillions. The honest takeaway is directional: the market is growing fast, but any single dollar figure is more marketing than measurement.

Insurtech is not one market but several. Property and casualty commands the largest insurtech share (one estimate puts it near 59% in 2025), reflecting how auto, home, and cyber lend themselves to data, telematics, and automation (see the table below). Health is the fastest-growing application, moving from roughly a quarter of activity toward a third.

On the deployment side, on-premise software still holds more than 60% of the market, because insurers prize data security, control, and regulatory compliance. Cloud is gaining share for its flexibility, but the regulated nature of insurance keeps adoption more conservative than in other fintech verticals.

The biggest structural shift is embedded insurance: coverage sold inside another purchase, like travel cover at checkout or device protection with a phone. Deloitte and others project embedded gross written premium could reach roughly $700 billion by 2030, and some forecasts see it hitting about 15% of global premium (around $1.1 trillion) by 2033.

The mechanism is distribution. Instead of a startup carrier fighting to acquire customers, insurance rides along with a purchase the customer is already making, at near-zero marginal acquisition cost. Over 76% of embedded placements already flow through digital and API-first channels, which is why so many insurtechs now sell infrastructure rather than policies.

The United States dominates, but the internal map is shifting. Silicon Valley's share of global insurtech funding halved from 20% in 2023 to 10% in 2024, and New York overtook it at 15%. North America broadly holds an estimated 38-48% of the market depending on the source.

Asia Pacific is the fastest-growing region, propelled by smartphone penetration, digital-first consumers, and lighter legacy insurance infrastructure. Europe remains a strong secondary hub, particularly for commercial and specialty lines and for the reinsurer-backed capital that increasingly funds the sector.

The listed insurtechs finally look like real insurers (see the chart and table below). Health-focused Oscar Health booked $11.7 billion in FY2025 revenue, dwarfing the P&C names. Among property and auto players, Root grew revenue 29% to $1.52 billion and turned a $40.3 million profit, while Hippo swung to a $58 million net income on $468.6 million of revenue.

Lemonade, the best-known name, is still scaling toward profitability: about $662 million of guided FY2025 revenue, roughly $1.2 billion of in-force premium, some 2.87 million customers, and a net loss narrowing to about $37.5 million. The through-line across all four is a hard pivot from growth to underwriting discipline (company filings).

Insurtech has completed a full hype cycle: euphoria in 2021, a savage 2022-2024 reset, and a leaner recovery in 2025. The survivors are companies that learned to underwrite, and the public names now show real revenue, improving loss ratios, and, in several cases, actual profits, a very different picture from the cash-burning stories of a few years ago.

For an investor, the lesson is discipline over narrative. This is not investment advice, but the sector's own history is a case study in why unit economics and a path to profitability matter more than a growth chart. If you want exposure to the theme, spreading it across several names, and weighing valuation against those real earnings, beats betting on any single disruptor.